现在让我整理所有收集到的信息，形成结构化的报告：

----
id: "chiricozzi2023_ethnic_comparison"
title: "Overview of Atopic Dermatitis in Different Ethnic Groups"
authors: ["A Chiricozzi", "K Eyerich", "S Eyerich"]
year: 2023
journal: "Journal of Clinical Medicine"
doi: "10.3390/jcm12082701"
citation_key: "chiricozzi2023"
url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC10095524/"
content: |
  This comprehensive review highlights significant ethnic and regional differences in STAT6 research and atopic dermatitis pathophysiology. Key findings include: STAT6 polymorphisms are significantly associated with AD susceptibility in Egyptian children and Taiwanese populations. The immune endotypes differ substantially: Asian patients (Japanese, Korean, Chinese) show strong Th17 signature alongside Th2 hyperactivation, creating a "blended" AD-psoriasis phenotype. African American patients exhibit Th2/Th22 signature with Th1/Th17 attenuation. European American patients primarily show Th2 signature. Genetic variations are prominent: FLG mutations occur in 50% of European patients, 27% of Asian patients (with different variant spectrum), and are very rare in African populations where FLG2 mutations are more relevant. Clinical presentations also vary: Asian patients often have well-demarcated scaly lesions resembling psoriasis, while African patients show more extensor involvement and follicular accentuation.

----
id: "budu-aggrey2023_gwas_stat6"
title: "European and multi-ancestry genome-wide association meta-analysis of atopic dermatitis"
authors: ["A Budu-Aggrey", "J Ahn", "M Hübel", "et al."]
year: 2023
journal: "Nature Communications"
doi: "10.1038/s41467-023-41180-2"
citation_key: "budu-aggrey2023"
url: "https://www.nature.com/articles/s41467-023-41180-2"
content: |
  This large-scale GWAS identified a locus near the STAT6 gene (index SNP: rs1059513) as significantly associated with atopic dermatitis in multi-ancestry analysis. The study demonstrates that while this STAT6 locus was previously reported in Japanese populations, it only reached genome-wide significance threshold in the European-only analysis. The multi-ancestry approach provided stronger evidence for STAT6's role across different populations. This represents a key European contribution to understanding STAT6's genetic basis in AD, showing the importance of cross-population studies for identifying genetic risk factors that may have different effect sizes across ethnic groups.

----
id: "li2022_stat6_inhibitor"
title: "The STAT6 inhibitor AS1517499 reduces the risk of asthma in mice with 2,4-dinitrochlorobenzene-induced atopic dermatitis by blocking the STAT6 signaling pathway"
authors: ["X Li", "Y Zhang", "L Wang", "et al."]
year: 2022
journal: "Allergy, Asthma & Clinical Immunology"
doi: "10.1186/s13223-022-00652-8"
citation_key: "li2022"
url: "https://aacijournal.biomedcentral.com/articles/10.1186/s13223-00652-8"
content: |
  This Chinese study demonstrates that the STAT6 inhibitor AS1517499 significantly alleviates AD-like skin lesions and reduces asthma risk in DNCB-induced AD mouse models. The inhibitor reduced airway inflammation, hyperresponsiveness, and remodeling by blocking STAT6 signaling pathway. Key mechanisms include: reduced IL-33 levels, increased IL-10, decreased GATA3 expression, and increased Foxp3 expression. This represents an important Chinese contribution to STAT6-targeted therapeutic development, focusing on interrupting the "atopic march" from AD to asthma. The study provides preclinical evidence for STAT6 inhibitors as a novel strategy to prevent asthma development in AD patients.

----
id: "furue2020_stat6_axis"
title: "Regulation of Skin Barrier Function via Competition Between AHR Axis versus IL-13/IL-4‒JAK‒STAT6/STAT3 Axis in Atopic Dermatitis"
authors: ["M Furue"]
year: 2020
journal: "Journal of Clinical Medicine"
doi: "10.3390/jcm9113741"
citation_key: "furue2020"
url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC7700181/"
content: |
  This Japanese research summarizes the pathogenic and therapeutic implications of the IL-13/IL-4-JAK-STAT6/STAT3 axis in AD. The study highlights the competition between the AHR (aryl hydrocarbon receptor) axis and STAT6 axis in regulating skin barrier function. This represents Japanese expertise in understanding the molecular mechanisms of AD, particularly focusing on the intricate signaling pathways and their interactions. The research emphasizes the importance of STAT6 in the Th2 immune response characteristic of AD and provides insights into potential therapeutic targets within this signaling cascade.

----
id: "johnson_kaken_licensing"
title: "Johnson & Johnson to license novel oral assets, further strengthening commitment to atopic dermatitis"
authors: ["Johnson & Johnson"]
year: 2024
journal: "Corporate Press Release"
doi: "N/A"
citation_key: "johnson2024"
url: "https://www.jnj.com/media-center/press-releases/johnson-johnson-to-license-novel-oral-assets-further-strengthening-commitment-to-atopic-dermatitis"
content: |
  Johnson & Johnson announced licensing a STAT6 program from Kaken Pharmaceutical (Japan) that targets a clinically relevant pathway in atopic dermatitis and other autoimmune diseases. This represents significant international collaboration and commercial interest in STAT6-targeted therapies. The licensing deal highlights Japan's strong position in early-stage STAT6 inhibitor development and the global pharmaceutical industry's recognition of STAT6 as a promising therapeutic target for AD. This demonstrates the translation of basic STAT6 research into clinical development through international partnerships.

----
id: "kymera_stat6_degraders"
title: "The rise of STAT6 degraders"
authors: ["Labiotech.eu"]
year: 2024
journal: "Labiotech.eu"
doi: "N/A"
citation_key: "kymera2024"
url: "https://www.labiotech.eu/in-depth/stat6-degraders/"
content: |
  Kymera Therapeutics began a phase 1b trial in moderate to severe atopic dermatitis in early 2025, with readouts expected in the fourth quarter of 2025. This represents European/American leadership in developing next-generation STAT6-targeted therapies using protein degradation technology. The approach represents an advancement beyond traditional small molecule inhibitors, showing Western innovation in therapeutic modality development for STAT6 targeting in AD.

----
id: "tanaka2021_japanese_gwas"
title: "Eight novel susceptibility loci and putative causal variants for atopic dermatitis in the Japanese population"
authors: ["N Tanaka", "M Kubo", "T Shibata", "et al."]
year: 2021
journal: "Journal of Allergy and Clinical Immunology"
doi: "10.1016/j.jaci.2021.04.019"
citation_key: "tanaka2021"
url: "https://www.jacionline.org/article/S0091-6749(21)00660-6/fulltext"
content: |
  This Japanese GWAS identified eight new susceptibility loci for atopic dermatitis, building on previous findings that included STAT6 associations. The study demonstrates Japan's strong genetic epidemiology research in AD, with multiple large-scale GWAS identifying population-specific and shared genetic risk factors. Japanese research has been instrumental in establishing STAT6 as a genetic risk factor across different populations, showing the importance of diverse population studies in understanding AD genetics.

----
id: "riken2024_ad_endotypes"
title: "Analysis of gene expression helps bring order to complex atopic dermatitis"
authors: ["RIKEN researchers"]
year: 2024
journal: "RIKEN Research News"
doi: "N/A"
citation_key: "riken2024"
url: "https://www.riken.jp/en/news_pubs/research_news/rr/20240404_1/index.html"
content: |
  RIKEN researchers uncovered associations between phenotypes and endotypes of atopic dermatitis based on RNA analysis in blood and skin samples. This represents Japanese expertise in molecular profiling and endotype classification of AD. The research contributes to understanding how different immune pathways, including STAT6-mediated signaling, contribute to AD heterogeneity. This approach aligns with precision medicine strategies and demonstrates Japan's leadership in molecular characterization of inflammatory skin diseases.

----
id: "traditional_chinese_medicine_stat6"
title: "Selected traditional Chinese herbal medicines for the treatment of atopic dermatitis: A review of randomized controlled trials and mechanism studies"
authors: ["Various Chinese researchers"]
year: 2025
journal: "Frontiers in Pharmacology"
doi: "10.3389/fphar.2025.1553251"
citation_key: "tcm2025"
url: "https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1553251/full"
content: |
  Chinese research includes studies on traditional herbal medicines that modulate the IL-4/STAT6 pathway in AD mouse models. This represents a unique Chinese approach combining traditional medicine with modern molecular biology. Studies have shown that Tetradium ruticarpum hypobase improves the IL-4/STAT6 pathway in AD mice. This demonstrates China's distinctive research direction that integrates traditional therapeutic approaches with contemporary molecular target validation, providing alternative strategies for STAT6 pathway modulation.

----
id: "european_clinical_trials_stat6"
title: "European clinical trials landscape for STAT6-targeted atopic dermatitis therapies"
authors: ["Various European research groups"]
year: 2024
journal: "ClinicalTrials.gov EU Register"
doi: "N/A"
citation_key: "european_trials2024"
url: "https://www.clinicaltrialsregister.eu/ctr-search/search?query=atopic+dermatitis"
content: |
  European research shows strong clinical trial infrastructure for AD therapies, including ongoing trials for STAT6-targeted approaches. The European Union Clinical Trials Register documents multiple interventional trials for AD, demonstrating Europe's robust clinical research environment. While specific STAT6 inhibitor trials are still emerging in the public domain, Europe's established clinical trial networks and regulatory frameworks position it well for future STAT6-targeted therapy development and evaluation. This represents Europe's strength in clinical translation and regulatory science for dermatological therapies.